Concomitant disruption of Apob is protective from hypercholesterolemia and atherosclerosis, and demonstrates the utility of somatic genome editing to validate potential therapeutic targets for metabolic liver disorders. This evidence concerns the gene APOB and familial hypercholesterolemia.